抗病毒疗法 – Medxy AI

Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant

By MedXY 04/24/2026

A real-world study reveals FCN/GCV combination therapy enhances 1-year survival in HHV-6B encephalitis post-CBT, particularly after neutrophil engraftment, compared to monotherapy. Findings underscore the need for tailored antiviral strategies based on hematologic recovery.

Clinical Updates Infectious Diseases news

Potent Inhibition of Hepatitis E Virus Replication by Bemnifosbuvir: Preclinical Evidence and Clinical Prospects

By MedXY 03/08/2026

Preclinical studies demonstrate that the nucleotide analogue bemnifosbuvir effectively suppresses Hepatitis E virus (HEV) replication, showing synergistic potential with ribavirin and a high genetic barrier to resistance.

Gastroenterology Infectious Diseases news

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection

By MedXY 02/25/2026

This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potential in future curative treatment strategies.

Clinical Updates Gastroenterology Infectious Diseases news

Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial

By MedXY 02/24/2026

This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.